DOCSLIB.ORG

Clinical Variability in Glycine Encephalopathy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinical Variability in Glycine Encephalopathy REVIEW Special Focus Clinical variability in glycine encephalopathy Julia B Hennermann Glycine encephalopathy (GCE) is an autosomal recessive error of glycine degradation, Otto Heubner Center for resulting in a poor outcome with severe mental retardation, intractable seizures and Pediatric & Adolescent Medicine, Charité spasticity. Milder variants with a significantly better outcome have been reported, but an Universitätsmedizin Berlin early prediction of the long-term outcome is not yet possible. With regard to the long-term Augustenburger Platz 1, outcome, the data reported in the literature of children with different GCE forms were 13353 Berlin, Germany compared. Determination of cerebrospinal fluid and plasma glycine concentrations at the Tel.: +49 304 5066 6191; Fax: +49 304 5056 6918; time of diagnosis were not useful in differentiating mild and severe outcomes. By contrast, [email protected] several clinical parameters correlate with a poor outcome: spastic quadriparesis, truncal hypotonia, typical electroencephalography patterns, congenital and cerebral malformations (e.g., corpus callosum hypoplasia). Hyperactivity, behavioral problems and choreiform movement disorders are associated with a milder outcome. Thus, prediction of the outcome of GCE may be facilitated by searching for selected clinical parameters. In addition, early neuroimaging may be a valuable tool in predicting the outcome of GCE. Glycine encephalopathy ([GCE]; synonym: intracellular free calcium accumulation resulting nonketotic hyperglycinemia; Online Mendelian in neuronal injury, with subsequent cell death Inheritance in Man [OMIM] 605899) is an and intractable seizures [1,5]. Furthermore, gly- autosomal recessive inborn error of glycine deg- cine is a neurotransmitter on the glycinergic radation resulting in an excessive accumulation receptors, located in the spinal cord and the of glycine in all tissues, particularly in the CNS. brain stem. Stimulation of these receptors has an Patients may be diagnosed biochemically by the inhibitory effect due to an enhanced chloride typical combination of an increase of glycine in permeability in the postsynaptic neurons, and is plasma and cerebrospinal fluid (CSF), with an likely to be involved in muscular hypotonia, neo- increased CSF–plasma glycine ratio. The under- natal apnea and hiccupping in children with lying defect is a deficiency of the glycine cleavage GCE [1]. The excitatory effect of these receptors system (GCS), an intramitochondrial enzyme on neural progenitor cells could be involved in complex made up of four different protein com- the malformations sometimes observed in ponents: the P-protein (a pyridoxal phosphate- patients with GCE [6]. dependent glycine decarboxylase [GLDC]), the As far as is predictable, the prevalence of GCE T-protein (a tetrahydrofolate-dependent protein seems to be approximately 1 in 60,000 [1,7]. Most [AMT]), the H-protein (a lipoic acid containing patients suffer from the severe neonatal form (clas- hydrogen-carrier protein [GCSH]), and the sic GCE), presenting in the first few days of life L-protein (lipoamide dehydrogenase) [1]. with muscular hypotonia, seizures, lethargy and Approximately 65–80% of children with GCE apnea, leading to an early death or severe global have a defect in the P-protein, with the rest hav- mental retardation, intractable seizures and spastic ing a defect in the T-protein. A defect in the quadriparesis. Patients with milder forms of GCE H-protein has been described in one single show variable degrees of mental retardation and Keywords: atypical patient. Abnormalities in the L-protein have not seizures, behavioral problems and choreoiform nonketotic hyperglycinemia, been reported in GCE [1–4]. movement disorders. Patients with transient GCE glycine cleavage system, Glycine functions both as an inhibitory and have rarely been described, mimicking the clinical glycine decarboxylase, glycine encephalopathy, hydrogen excitatory neurotransmitter. It acts as a neuro- and biochemical features of classic GCE during carrier protein, nonketotic modulator with an excitatory effect at the the neonatal period, but resulting in a good hyperglycinemia, outcome, N-methyl-D-aspartate (NMDA) receptor chan- neurological outcome with no, or only slight, neu- symptoms, tetrahydrofolate- dependent protein nel complex located in the cortex and the fore- rological sequelae [1,4]. An early prediction of the brain. GCS deficiency causes an accumulation of outcome of GCE at the time of manifestation is glycine in the synaptic cleft, leading to an over- not yet possible. In addition, an effective stimulation of the NMDA receptor at the gly- treatment does not exist. Current therapy is cine modulatory site. This causes an increased directed at decreasing the glycine concentration 10.2217/14796708.1.5.621 © 2006 Future Medicine Ltd ISSN 1479-6708 Future Neurol. (2006) 1(5), 621–630 621 REVIEW – Hennermann and at blocking the effect of glycine at neuro- outcome with a developmental quotient (DQ) of transmitter receptors. Glycine plasma concentra- less than 10. They have a developmental age of tions may be reduced by benzoate treatment and approximately 6 weeks old and may learn to by a low protein diet. The optional treatment smile, but only occasionally learn to grasp objects with NMDA receptor agonists includes dex- and/or to sit [10]. In contrast to children with mild trometorphane, ketamine and felbamate. Addi- GCE, they seldom show hyperactivity and/or tionally, combined anticonvulsive treatment is behavioral problems (Table 1). Approximately necessary in most children with GCE, mainly in 30% die during the neonatal period [9–10]. those with classic GCE. To facilitate the classifica- Long-term problems in patients with classic tion and prognosis of children with GCE findings GCE variably include feeding difficulties, bile on clinical symptoms, laboratory results, electro- stones, gastroesophageal reflux and esophagitis, encepholography (EEG) and neuroimaging of all some of which represent side effects of patients with a mild or transient form of GCE treatment [8]. Some children require gastric tube reported in the literature were compared with sur- feeding. Further problems involve the skeletal veys on children with classic GCE, this was system, including hip dislocation, scoliosis and mainly the survey performed by our group [8]. osteoporosis [1]. Females had been reported to show a more devastating course of the disease [9], Clinical course which was not confirmed by our data [8]. Classic glycine encephalopathy The typical clinical picture of GCE is that of chil- Mild glycine encephalopathy variants dren with classic GCE, which starts early in the All children with GCE have an impaired DQ of neonatal period with ensuing poor outcome. varying degrees, but 15–20% of them, termed During the first 3 days of life, at least two thirds mild GCE, show a significantly better clinical of the children present with muscular hypotonia, outcome, reaching a DQ of 25–80 [9–10]. They apnea and coma [8,9]. Seizures may occur during learn to walk and show some motor skills, but the neonatal period but also later during the first predominantly manifest severe speech retarda- 3 months of life. Some children show congenital tion. In contrast to classic GCE, children with malformations, including clump feet, cleft mild GCE are hyperactive and may develop lip/cleft palate, dysplastic ears, congenital hernias choreiform movement disorders and behavioral and cryptorchism; and children also frequently problems, mainly aggressive behavior. In the fol- show brain malformations. The occurrence of lowing, the clinical data of all patients with a these malformations always associates with a poor mild or transient form of GCE reported in the clinical course [4,10]. Patients develop spastic literature are compared with those of surveys on quadriparesis before 6 months of age, truncal children with classic GCE (Table 1). Enzymatic hypotonia, intractable seizures, severe global assays have been performed in only some children retardation, frequent hiccuping and microcephaly with mild GCE, these revealed a significantly (Table 1). Children with classic GCE show a poor reduced, but not null activity of GCS in liver Table 1. Clinical symptoms in different glycine encephalopathy forms, as reported in the literature. Clinical symptoms Mild neonatal GCE* Mild infantile GCE‡ Late onset GCE§ Classic GCE¶ Mental retardation 16/16 100% 23/25 92% 8/13 62% 23/23 100% including speech delay Muscular (truncal) 13/16 81% 14/25 56% 0/13 0% 23/23 100% hypotonia Spasticity# 3/16 19% 1/25 4% 5/13 38% 23/23 100% Seizures 11/16 69% 11/25 44% 1/13 8% 23/23 100% Choreoiform movement 7/16 44% 7/25 28% 3/13 23% 3/23 13% disorders Behavioral problems 10/16 63% 10/25 40% 6/13 46% 4/23 17% *[8,11–16]; ‡[8,13–15,17–28]; §[14,22,30–36]; ¶[8]; #Spasticity in late-onset GCE is described as a spastic diplegia caused by a progressive spinocerebellar degeneration [30–32]. Data of all patients with a mild or transient form of GCE reported in the literature are pooled and compared with those of surveys on children with classic GCE. GCE: Glycine encephalopathy. 622 Future Neurol. (2006) 1(5) Clinical variability in glycine encephalopathy – REVIEW tissue in all children tested. Therefore, mild GCE directly [35]. In conclusion, late onset GCE forms seem to be associated with a certain appears to display a different clinical entity of residual GCS activity. GCE, but GCS deficiency has never been proved Children with mild
Load more

Recommended publications
  • Clinical Issues in Neonatal Care
    Linda Ikuta , MN, RN, CCNS, PHN , and Ksenia Zukowsky, PhD, APRN, NNP-BC ❍ Section Editors Clinical Issues in Neonatal Care 2.5 HOURS Continuing Education Deconstructing Black Swans An Introductory Approach to Inherited Metabolic Disorders in the Neonate Nicholas Ah Mew , MD ; Sarah Viall , MSN, PPCNP ; Brian Kirmse , MD ; Kimberly A. Chapman , MD, PhD ABSTRACT Background: Inherited metabolic disorders (IMDs) are individually rare but collectively common disorders that frequently require rapid or urgent therapy. Purpose: This article provides a generalized approach to IMDs, as well as some investigations and safe therapies that may be initiated pending the metabolic consult. Methods/Search Strategy: An overview of the research supporting management strategies is provided. In addition, the newborn metabolic screen is reviewed. Findings/Results: Caring for infants with IMDs can seem difficult because each of the types is rarely seen; however, collectively the management can be seen as similar. Implications for Practice: When an IMD is suspected, a metabolic specialist should be consulted for expert advice regarding appropriate laboratory investigations and management. Because rapid intervention of IMDs before the onset of symptoms may prevent future irreversible sequelae, each abnormal newborn screen must be addressed promptly. Implications for Research: Management can be difficult. Research in this area is limited and can be difficult without multisite coordination since sample sizes of any significance are difficult to achieve. Key Words:
    [Show full text]
  • Inherited Metabolic Disease
    Inherited metabolic disease Dr Neil W Hopper SRH Areas for discussion • Introduction to IEMs • Presentation • Initial treatment and investigation of IEMs • Hypoglycaemia • Hyperammonaemia • Other presentations • Management of intercurrent illness • Chronic management Inherited Metabolic Diseases • Result from a block to an essential pathway in the body's metabolism. • Huge number of conditions • All rare – very rare (except for one – 1:500) • Presentation can be non-specific so index of suspicion important • Mostly AR inheritance – ask about consanguinity Incidence (W. Midlands) • Amino acid disorders (excluding phenylketonuria) — 18.7 per 100,000 • Phenylketonuria — 8.1 per 100,000 • Organic acidemias — 12.6 per 100,000 • Urea cycle diseases — 4.5 per 100,000 • Glycogen storage diseases — 6.8 per 100,000 • Lysosomal storage diseases — 19.3 per 100,000 • Peroxisomal disorders — 7.4 per 100,000 • Mitochondrial diseases — 20.3 per 100,000 Pathophysiological classification • Disorders that result in toxic accumulation – Disorders of protein metabolism (eg, amino acidopathies, organic acidopathies, urea cycle defects) – Disorders of carbohydrate intolerance – Lysosomal storage disorders • Disorders of energy production, utilization – Fatty acid oxidation defects – Disorders of carbohydrate utilization, production (ie, glycogen storage disorders, disorders of gluconeogenesis and glycogenolysis) – Mitochondrial disorders – Peroxisomal disorders IMD presentations • ? IMD presentations • Screening – MCAD, PKU • Progressive unexplained neonatal
    [Show full text]
  • Amino Acid Disorders
    471 Review Article on Inborn Errors of Metabolism Page 1 of 10 Amino acid disorders Ermal Aliu1, Shibani Kanungo2, Georgianne L. Arnold1 1Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA Contributions: (I) Conception and design: S Kanungo, GL Arnold; (II) Administrative support: S Kanungo; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: E Aliu, GL Arnold; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Georgianne L. Arnold, MD. UPMC Children’s Hospital of Pittsburgh, 4401 Penn Avenue, Suite 1200, Pittsburgh, PA 15224, USA. Email: [email protected]. Abstract: Amino acids serve as key building blocks and as an energy source for cell repair, survival, regeneration and growth. Each amino acid has an amino group, a carboxylic acid, and a unique carbon structure. Human utilize 21 different amino acids; most of these can be synthesized endogenously, but 9 are “essential” in that they must be ingested in the diet. In addition to their role as building blocks of protein, amino acids are key energy source (ketogenic, glucogenic or both), are building blocks of Kreb’s (aka TCA) cycle intermediates and other metabolites, and recycled as needed. A metabolic defect in the metabolism of tyrosine (homogentisic acid oxidase deficiency) historically defined Archibald Garrod as key architect in linking biochemistry, genetics and medicine and creation of the term ‘Inborn Error of Metabolism’ (IEM). The key concept of a single gene defect leading to a single enzyme dysfunction, leading to “intoxication” with a precursor in the metabolic pathway was vital to linking genetics and metabolic disorders and developing screening and treatment approaches as described in other chapters in this issue.
    [Show full text]
  • Genetics Newborn Screening Program Health Professional Fact Sheet
    Genetics Newborn Screening Program Health Professional Fact Sheet Nonketotic Hyperglycinemia (NKH) also known as Glycine Encephalopathy Introduction Nonketotic hyperglycinemia (NKH) is an autosomal recessive inborn error of glycine degradation in which large quantities of glycine accumulate in all body tissues, including the central nervous system. The defect is in the glycine cleavage enzyme complex (GCS) which catalyzes the major reaction of glycine degradation and is composed of four proteins (P-, H-, T-, and L-Protein) encoded on four different chromosomes. Defects in the P, H, and T proteins have been identified in NKH. Over 80 percent of patients with the neonatal phenotype have a defect in the P-protein. Later onset cases are more likely to have defects in the H- or T-proteins. Although glycine plays many roles in intermediary metabolism, the symptoms of NKH seem to relate to glycine’s function as a neurotransmitter. Clinical Features Neonatal form: Most patients have the neonatal phenotype, presenting in the first few days of life with lethargy, hypotonia, and refusal to feed. Wandering eye movements and intermittent ophthalmoplegia are frequent. Most patients have normal to increased deep-tendon reflexes. As the encephalopathy progresses to coma, the infants develop frequent segmental myoclonic jerks, apneic episodes, and hiccups. Even with respiratory support, approximately 30 percent of patients die in the neonatal period. Those who regain spontaneous respiration develop intractable seizures and profound mental retardation. Routine laboratory studies of children with NKH are remarkably normal, given the severe neurologic abnormalities. The only consistent abnormality is elevation of glycine concentrations in urine, plasma, and cerebrospinal fluid.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0281166 A1 BHATTACHARJEE Et Al
    US 20160281 166A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0281166 A1 BHATTACHARJEE et al. (43) Pub. Date: Sep. 29, 2016 (54) METHODS AND SYSTEMIS FOR SCREENING Publication Classification DISEASES IN SUBJECTS (51) Int. Cl. (71) Applicant: PARABASE GENOMICS, INC., CI2O I/68 (2006.01) Boston, MA (US) C40B 30/02 (2006.01) (72) Inventors: Arindam BHATTACHARJEE, G06F 9/22 (2006.01) Andover, MA (US); Tanya (52) U.S. Cl. SOKOLSKY, Cambridge, MA (US); CPC ............. CI2O 1/6883 (2013.01); G06F 19/22 Edwin NAYLOR, Mt. Pleasant, SC (2013.01); C40B 30/02 (2013.01); C12O (US); Richard B. PARAD, Newton, 2600/156 (2013.01); C12O 2600/158 MA (US); Evan MAUCELI, (2013.01) Roslindale, MA (US) (21) Appl. No.: 15/078,579 (57) ABSTRACT (22) Filed: Mar. 23, 2016 Related U.S. Application Data The present disclosure provides systems, devices, and meth (60) Provisional application No. 62/136,836, filed on Mar. ods for a fast-turnaround, minimally invasive, and/or cost 23, 2015, provisional application No. 62/137,745, effective assay for Screening diseases, such as genetic dis filed on Mar. 24, 2015. orders and/or pathogens, in Subjects. Patent Application Publication Sep. 29, 2016 Sheet 1 of 23 US 2016/0281166 A1 SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS S{}}\\93? sau36 Patent Application Publication Sep. 29, 2016 Sheet 2 of 23 US 2016/0281166 A1 &**** ? ???zzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzz??º & %&&zzzzzzzzzzzzzzzzzzzzzzz &Sssssssssssssssssssssssssssssssssssssssssssssssssssssssss & s s sS ------------------------------ Patent Application Publication Sep. 29, 2016 Sheet 3 of 23 US 2016/0281166 A1 23 25 20 FG, 2. Patent Application Publication Sep. 29, 2016 Sheet 4 of 23 US 2016/0281166 A1 : S Patent Application Publication Sep.
    [Show full text]
  • Amino Acid Disorders Detected by Quantitative Amino Acid HPLC Analysis in Thailand: an Eight-Year Experience
    ارا ه ت ه از $&% #ت "! Clinica Chimica Acta 413 (2012) 1141–1144 Contents lists available at SciVerse ScienceDirect Clinica Chimica Acta journal homepage: www.elsevier.com/locate/clinchim Amino acid disorders detected by quantitative amino acid HPLC analysis in Thailand: An eight-year experience Nithiwat Vatanavicharn ⁎, Pisanu Ratanarak, Somporn Liammongkolkul, Achara Sathienkijkanchai, Pornswan Wasant Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand article info abstract Article history: Background: Amino acid disorders are a major group of inborn errors of metabolism (IEM) with variable clin- Received 13 October 2011 ical presentations. This study was aimed to provide the data of amino acid disorders detected in high-risk Received in revised form 16 March 2012 Thai patients referred to our metabolic lab from all over the country. Accepted 20 March 2012 Methods: From 2001 to 2009, we analyzed amino acids by HPLC in 1214 plasma and cerebrospinal fluid spec- Available online 23 March 2012 imens. These specimens were obtained from patients with clinical suspicion of IEM or with positive newborn screening. The clinical data of the patients with confirmed diagnoses of amino acid disorders were also ana- Keywords: lyzed. Amino acid disorders HPLC Results: Fifty-eight patients were diagnosed with amino acid disorders, including 20 cases (34.5%) with maple Thailand syrup urine disease, 13 (22.4%) with phenylketonuria and hyperphenylalaninemia, 13 (22.4%) with nonke- totic hyperglycinemia, 9 (15.5%) with urea cycle defects, 2 (3.4%) with classical homocystinuria, and 1 (1.7%) with ornithine aminotransferase deficiency. There was considerable delay in diagnoses which led to poor outcomes in most patients.
    [Show full text]
  • Downloaded from the App Store and Nucleobase, Nucleotide and Nucleic Acid Metabolism 7 Google Play
    Hoytema van Konijnenburg et al. Orphanet J Rare Dis (2021) 16:170 https://doi.org/10.1186/s13023-021-01727-2 REVIEW Open Access Treatable inherited metabolic disorders causing intellectual disability: 2021 review and digital app Eva M. M. Hoytema van Konijnenburg1†, Saskia B. Wortmann2,3,4†, Marina J. Koelewijn2, Laura A. Tseng1,4, Roderick Houben6, Sylvia Stöckler‑Ipsiroglu5, Carlos R. Ferreira7 and Clara D. M. van Karnebeek1,2,4,8* Abstract Background: The Treatable ID App was created in 2012 as digital tool to improve early recognition and intervention for treatable inherited metabolic disorders (IMDs) presenting with global developmental delay and intellectual disabil‑ ity (collectively ‘treatable IDs’). Our aim is to update the 2012 review on treatable IDs and App to capture the advances made in the identifcation of new IMDs along with increased pathophysiological insights catalyzing therapeutic development and implementation. Methods: Two independent reviewers queried PubMed, OMIM and Orphanet databases to reassess all previously included disorders and therapies and to identify all reports on Treatable IDs published between 2012 and 2021. These were included if listed in the International Classifcation of IMDs (ICIMD) and presenting with ID as a major feature, and if published evidence for a therapeutic intervention improving ID primary and/or secondary outcomes is avail‑ able. Data on clinical symptoms, diagnostic testing, treatment strategies, efects on outcomes, and evidence levels were extracted and evaluated by the reviewers and external experts. The generated knowledge was translated into a diagnostic algorithm and updated version of the App with novel features. Results: Our review identifed 116 treatable IDs (139 genes), of which 44 newly identifed, belonging to 17 ICIMD categories.
    [Show full text]
  • Model Mice for Mild-Form Glycine Encephalopathy: Behavioral And
    0031-3998/08/6403-0228 Vol. 64, No. 3, 2008 PEDIATRIC RESEARCH Printed in U.S.A. Copyright © 2008 International Pediatric Research Foundation, Inc. ARTICLES Model Mice for Mild-Form Glycine Encephalopathy: Behavioral and Biochemical Characterizations and Efficacy of Antagonists for the Glycine Binding Site of N-Methyl D-Aspartate Receptor KANAKO KOJIMA-ISHII, SHIGEO KURE, AKIKO ICHINOHE, TOSHIKATSU SHINKA, AYUMI NARISAWA, SHOKO KOMATSUZAKI, JUNNKO KANNO, FUMIAKI KAMADA, YOKO AOKI, HIROYUKI YOKOYAMA, MASAYA ODA, TAKU SUGAWARA, KAZUO MIZOI, DAIICHIRO NAKAHARA, AND YOICHI MATSUBARA Department of Medical Genetics [K.K.-I., S.K., A.I., T.S., A.N., S.K., J.K., F.K., Y.A., Y.M.], Department of Pediatrics [H.Y.], Tohoku University School of Medicine, Miyagi, 980-8574, Japan; Department of Neurosurgery [M.O., T.S., K.M.], Akita University School of Medicine, Akita, 010-8502, Japan; Department of Psychology [D.N.], Hamamatsu University School of Medicine, Shizuoka, 431-3192, Japan ABSTRACT: Glycine encephalopathy (GE) is caused by an inher- genase, which are encoded by GLDC, AMT, GCSH and GCSL, ited deficiency of the glycine cleavage system (GCS) and character- respectively (2). A defect of any component can lead to ized by accumulation of glycine in body fluids and various neuro- defective overall activity of the GCS. GLDC, AMT and GCSH logic symptoms. Coma and convulsions develop in neonates in mutations have been reported in GE patients (3,4). Patients typical GE while psychomotor retardation and behavioral abnormal- with typical GE have severe symptoms such as convulsions, ities in infancy and childhood are observed in mild GE.
    [Show full text]
  • Glycine Encephalopathy, AMT-Related
    Glycine encephalopathy What is glycine encephalopathy? Glycine encephalopathy is an inherited metabolic disease that, in its typical form, is characterized by seizures in infancy and other progressive nervous system problems. Individuals with glycine encephalopathy have an abnormally low level of an enzyme that helps to breaks down the amino acid glycine. Symptoms are due to a toxic build-up of glycine, especially in the brain.1 Glycine encephalopathy is also known as non-ketotic hyperglycinemia.2 What are the symptoms of glycine encephalopathy and what treatment is available? Glycine encephalopathy is a disease that varies in severity and age at presentation. The majority of individuals with glycine encephalopathy show symptoms within the first few days of life, and a subset of individuals with early onset may also have birth defects (such as cleft lip/palate or club feet). Some individuals may show less severe symptoms later in infancy or childhood.1,2 Symptoms may include:1,2 • Seizures that may not respond to treatment • Lethargy • Hypotonia (low muscle tone) • Difficulty breathing • Hiccupping • Feeding difficulties • Intellectual disability and possible behavior problems • Coma and possible death There is no cure for glycine encephalopathy. Treatment includes supportive care for symptoms including medicine to help reduce levels of glycine in the blood and control seizures. A ketogenic diet, feeding and respiratory support, and physical therapy may improve symptoms in some individuals.2 Without intervention, individuals with severe glycine encephalopathy often do not survive past infancy.1 Glycine encephalopathy is included on newborn screening profiles in some states in the US.3 How is glycine encephalopathy inherited? Glycine encephalopathy is an autosomal recessive disease caused by mutations in one of three different genes.
    [Show full text]
  • A Novel Intronic Homozygous Mutation in the AMT Gene of a Patient with Nonketotic Hyperglycinemia and Hyperammonemia
    Metabolic Brain Disease (2019) 34:373–376 https://doi.org/10.1007/s11011-018-0317-0 SHORT COMMUNICATION A novel intronic homozygous mutation in the AMT gene of a patient with nonketotic hyperglycinemia and hyperammonemia Sarah Silverstein1 & Aravindhan Veerapandiyan2 & Caroline Hayes-Rosen1 & Xue Ming1 & Jeffrey Kornitzer1 Received: 26 June 2018 /Accepted: 12 September 2018 /Published online: 22 October 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Nonketotic Hyperglycinemia is an autosomal recessive disorder characterized by defects in the mitochondrial glycine cleavage system. Most patients present soon after birth with seizures and hypotonia, and infants that survive the newborn period often have profound intellectual disability and intractable seizures. Here we present a case report of a 4-year-old girl with NKH as well as hyperammonemia, an uncommon finding in NKH. Genetic analysis found a previously unreported homozygous mutation (c.878–1 G > A) in the AMT gene. Maximum Entropy Principle modeling predicted that this mutation most likely breaks the splice site at the border of intron 7 and exon 8 of the AMT gene. Treatment with L-Arginine significantly reduced both the proband’s glycine and ammonia levels, in turn aiding in control of seizures and mental status. This is the first time the use of L- Arginine is reported to successfully treat elevated glycine levels. Keywords Glycine encephalopathy . Genetics . Hyperammonemia . L-arginine . Maximum entropy principle modeling Introduction removal of carbon dioxide from glycine and attaches the re- mainder of the glycine molecule to the H subunit. The T sub- Nonketotic hyperglycinemia (NKH) is an autosomal recessive unit, amino methyltransferase (AMT), catalyzes the produc- disorder characterized by defects in the mitochondrial glycine tion of N5, N10-methylene-H4folate and ammonia in the cleavage system (GCS).
    [Show full text]
  • The Myriad Foresight® Carrier Screen
    The Myriad Foresight® Carrier Screen 180 Kimball Way | South San Francisco, CA 94080 www.myriadwomenshealth.com | [email protected] | (888) 268-6795 The Myriad Foresight® Carrier Screen - Disease Reference Book 11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia ...............................................................................................................................................................................8 6-pyruvoyl-tetrahydropterin Synthase Deficiency....................................................................................................................................................................................................10 ABCC8-related Familial Hyperinsulinism..................................................................................................................................................................................................................12 Adenosine Deaminase Deficiency ............................................................................................................................................................................................................................14 Alpha Thalassemia ....................................................................................................................................................................................................................................................16 Alpha-mannosidosis ..................................................................................................................................................................................................................................................18
    [Show full text]
  • Why Not Glycine Electrochemical Biosensors?
    sensors Perspective Why Not Glycine Electrochemical Biosensors? Clara Pérez-Ràfols , Yujie Liu , Qianyu Wang , María Cuartero and Gastón A. Crespo * Department of Chemistry, School of Engineering Science in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Teknikringen 30, SE-100 44 Stockholm, Sweden; [email protected] (C.P.-R.); [email protected] (Y.L.); [email protected] (Q.W.); [email protected] (M.C.) * Correspondence: [email protected] Received: 30 June 2020; Accepted: 16 July 2020; Published: 21 July 2020 Abstract: Glycine monitoring is gaining importance as a biomarker in clinical analysis due to its involvement in multiple physiological functions, which results in glycine being one of the most analyzed biomolecules for diagnostics. This growing demand requires faster and more reliable, while affordable, analytical methods that can replace the current gold standard for glycine detection, which is based on sample extraction with subsequent use of liquid chromatography or fluorometric kits for its quantification in centralized laboratories. This work discusses electrochemical sensors and biosensors as an alternative option, focusing on their potential application for glycine determination in blood, urine, and cerebrospinal fluid, the three most widely used matrices for glycine analysis with clinical meaning. For electrochemical sensors, voltammetry/amperometry is the preferred readout (10 of the 13 papers collected in this review) and metal-based redox mediator modification is the predominant approach for electrode fabrication (11 of the 13 papers). However, none of the reported electrochemical sensors fulfill the requirements for direct analysis of biological fluids, most of them lacking appropriate selectivity, linear range of response, and/or capability of measuring at physiological conditions.
    [Show full text]